Total number of shares and voting rights in Zealand Pharma at August 31, 2023
31. August 2023 11:30 ET
|
Zealand Pharma
Company announcement – No. 32 / 2023 Copenhagen, Denmark, August 31, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on...
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
30. August 2023 01:33 ET
|
Zealand Pharma
Company announcement – No. 31 / 2023 Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism US FDA has granted priority review...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
25. August 2023 10:45 ET
|
Zealand Pharma
Company announcement – No. 30 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
24. August 2023 16:00 ET
|
Zealand Pharma
Company announcement – No. 29 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 24, 2023 – Zealand Pharma A/S...
Zealand Pharma Announces Financial Results for the First Half of 2023
17. August 2023 01:00 ET
|
Zealand Pharma
Company announcement - No. 28 / 2023 Zealand Pharma Announces Financial Results for the First Half of 2023 Strong progress across R&D pipeline and significant strengthening of the balance...
Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results
14. August 2023 11:05 ET
|
Zealand Pharma
Press Release – No. 9 / 2023 Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results Copenhagen, Denmark, August 14, 2023 – a Zealand...
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
03. Juli 2023 06:01 ET
|
Zealand Pharma
Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396...
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
30. Juni 2023 13:32 ET
|
Zealand Pharma
Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S...
Total number of shares and voting rights in Zealand Pharma at June 30, 2023
30. Juni 2023 11:05 ET
|
Zealand Pharma
Company announcement – No. 26 / 2023 Total number of shares and voting rights in Zealand Pharma at June 30, 2023 Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL)...
Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency
26. Juni 2023 02:30 ET
|
Zealand Pharma
Press release – No. 7 / 2023 Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency ...